KQ-2002 / Novatim Immune Therap - LARVOL DELTA

Keyi Pharmaceuticals' enhanced dual-target CAR-T cell gene therapy product KQ-2002 was approved for clinical trials [Google translation] (bydrug.pharmcube.com) - "On November 25, 2024, according to the official website of CDE, the CD19&CD22 enhanced dual-target autologous CAR-T product KQ-2002 independently developed by Keyi (Zhejiang) Pharmaceutical Technology Co., Ltd. from the source is intended to be used to treat adult relapsed/refractory acute B-cell lymphoma and relapsed/refractory B-cell non-Hodgkin's lymphoma, and has obtained the implicit approval of clinical trials from the Center for Drug Evaluation of the National Medical Products Administration (CDE)."

New trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Keyi Pharmaceuticals' CD19 & CD22 Dual-Target CAR-T Cell Injection IND Received [Google translation] (bydrug.pharmcube.com) - "Public information shows that KQ-2002 CAR-T cell injection is a CD19 & CD22 enhanced dual-target autologous CAR-T product independently developed by Keyi Pharmaceuticals, intended for the treatment of high-grade B-cell lymphoma."

New trial • Hematological Malignancies • Lymphoma • Oncology

KQ-2002-XC001: CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Rong Tao

CAR T-Cell Therapy • New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology